Unipharma Co (ROCO:6621) ROE % Adjusted to Book Value: -7.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6621 Unipharma Co Ltd ROCO:6621
74 GF Score
Price NT$11.30
GF Value NT$11.58
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Unipharma Co ROE % Adjusted to Book Value?

Unipharma Co ROCO:6621 -3.42% 74 ROE % Adjusted to Book Value is -7.40% as of Dec. 2025. GuruFocus rates ROCO:6621 with a GF Score™ of 74/100 and a GF Value™ of NT$11.58 (Fairly Valued). The stock has 2 warning signs investors should review.

Unipharma Co's ROE % for the quarter that ended in Dec. 2025 was -13.91%. Unipharma Co's PB Ratio for the quarter that ended in Dec. 2025 was 1.88. Unipharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -7.40%.

Unipharma Co ROE % Adjusted to Book Value Related Terms

Unipharma Co ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Unipharma Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unipharma Co ROE % Adjusted to Book Value Chart

Unipharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.06 -1.18 -4.21 -4.80 -8.38

Unipharma Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.37 -3.33 -5.88 -9.07 -7.40

ROCO:6621 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unipharma Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Unipharma Co's ROE % Adjusted to Book Value falls into.


ROCO:6621
74GF Score
Unipharma Co Ltd ROCO:6621
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unipharma Co ROE % Adjusted to Book Value Calculation

Unipharma Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-15.76% / 1.88
=-8.38%

Unipharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-13.91% / 1.88
=-7.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -7.40% mean?
Unipharma Co (ROCO:6621) has a ROE % Adjusted to Book Value of -7.40% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Unipharma Co and its competitors.
Is Unipharma Co's ROE % Adjusted to Book Value too high?
Unipharma Co's current ROE % Adjusted to Book Value is -7.40%. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Unipharma Co's ROE % Adjusted to Book Value of -7.40% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Unipharma Co and its competitors. Unipharma Co's current ROE % Adjusted to Book Value is -7.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.58, compared to a current price of NT$11.30 — trading 2.4% below its estimated fair value. The current ROE % Adjusted to Book Value is -7.40%. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current ROE % Adjusted to Book Value is -7.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unipharma Co (ROCO:6621) Overvalued in 2026?

Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued. The current stock price of NT$11.30 is trading 2.4% below its estimated GF Value™ of NT$11.58. GuruFocus considers Unipharma Co to be Fairly Valued.

Key valuation signals for ROCO:6621:

  • ROE % Adjusted to Book Value: -7.40%
  • GF Value™: NT$11.58 vs. price of NT$11.30 (2.4% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Unipharma Co Business Description

Address Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score

Get the complete analysis for ROCO:6621

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$11.30
Price
NT$11.58
GF Value